替格瑞洛与氯吡格雷的药效观察及与CYP2C19基因多态性的关系
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

xys978088@163.com


Efficacies of ticagrelor and clopidogrel and their correlation with CYP2C19 gene polymorphisms in patients with acute coronary syndrome
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 观察替格瑞洛和氯吡格雷的临床疗效,并探讨其与CYP2C19 基因多态性的关系。方法 入选2013年3月至2014年3月在西安市唐都医院心内科接受住院治疗的急性冠脉综合征患者450例。根据拟选取的治疗方案,将所有患者随机分为两组:替格瑞洛组(n=227)和氯吡格雷组(n=223)。随访6个月,观察两组患者主要心脏不良事件(MACE)发生率。根据是否携带失功基因将两组患者再分别分为两亚组:携带组和非携带组。分别观察两亚组患者的MACE发生率和治疗期间出血并发症发生情况。结果 替格瑞洛组与氯吡格雷组中:非携带组患者MACE的发生率分别为8.4%和8.2%,差异无统计学意义(P>0.05);携带组患者MACE的发生率分别为9.1%和15.2%,差异有统计学意义(P<0.01)。各组内及组间出血并发症差异无统计学意义(P>0.05)。结论 与氯吡格雷相比,应用替格瑞洛治疗急性冠脉综合征,可进一步减少患者心血管事件风险,其机制与是否携带CYP2C19 功能丧失性等位基因有关。

    Abstract:

    Objective To observe the clinical efficacies of ticagrelor and clopidogrel and investigate their correlation with CYP2C19 gene polymorphisms. Methods A total of 450 hospitalized patients with acute coronary syndrome in our department from March 2013 to March 2014 were recruited in this study. According to their treatment regimes, the patients were randomly divided into the ticagrelor group (n=227) and the clopidogrel group (n=223). Their incidence of the major adverse cardiac events (MACE) was compared in the 6 months’ follow-up. The patients were also assigned into 2 subgroups according to their carrying CYP2C19*2/*3 loss-of-function allele or not. The incidence of the MACE and bleeding events were compared between the subgroups in the follow-up. Results Between the ticagrelor group and clopidogrel group, the incidence of MACE was 8.4% and 8.2% respectively for the non-carriers of CYP2C19*2/*3 loss-of-function allele, though without significant difference (P>0.05), and was 9.1% and 15.2% separately for the carriers, with obvious difference (P<0.01). However, there was no statistical difference in the incidence of bleeding events between the ticagrelor and clopidogrel groups and between the carriers and non-carriers (P>0.05). Conclusion Ticagrelor is superior to clopidogrel in decreasing the risk of MACE in the patients with acute coronary syndrome, which may be associated with carrying CYP2C19 loss-of-function allele or not.

    参考文献
    相似文献
    引证文献
引用本文

王 彬,薛玉生*,倪四峰,于 亮,尚福军.替格瑞洛与氯吡格雷的药效观察及与CYP2C19基因多态性的关系[J].中华老年多器官疾病杂志,2016,15(02):131-134
DOI:10.11915/j. issn.1671-5403.2016.02.031

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2015-10-11
  • 最后修改日期:2015-11-30
  • 录用日期:2015-11-30
  • 在线发布日期: 2016-02-22
  • 出版日期:
文章二维码